Friday’s deal with fits neatly within AstraZeneca’s business development strategy of upping investments in AI and in China.

VOV.VN - Prime Minister Pham Minh Chinh has proposed that AstraZeneca consider building a pharmaceutical manufacturing plant ...

Given that the Australian government heavily subsidizes pharmaceuticals— spending more than $AU16.7 billion annually through the Pharmaceutical Benefits Scheme (PBS)—there is both a strong moral and ...

Once hailed as the future of immuno-oncology, it’s been a tough few months for any remaining fans of anti-TIGIT antibodies. | ...

AstraZeneca has signed a deal worth up to $5.2bn to work with a Chinese biotech company using AI to develop new treatments for chronic diseases.

AstraZeneca has signed an AI-led research agreement with China's CSPC Pharmaceutical Group worth up to $5.3 billion, which ...

AstraZeneca has returned to recent licensing partner CSPC Pharmaceuticals with $110 million in upfront cash to start work on ...

AstraZeneca said it entered into a strategic research collaboration with China's CSPC Pharmaceuticals, focused on artificial intelligence-driven research, valued at up to $5.33 billion.

The deal with China’s CSPC Pharmaceuticals, focused on AI-driven research, aims to advance the discovery and development of ...

AstraZeneca has signed a research agreement worth more than $5 billion with Chinese drugmaker CSPC Pharmaceutical Group, the ...

Researchers from King's College London have called for urgent changes to the way new antibiotics are developed to address the ...

AstraZeneca said on Friday it has agreed to a research deal with Chinese drugmaker CSPC Pharmaceuticals worth up to $5.22 billion to focus on AI-enabled initiatives.